Phospholipase A2 expression in prostate cancer as a biomarker of good prognosis: A comprehensive study in patients with long follow-up.

Autor:	Recuero SDC; Department of Urology, Faculdade de Medicina da Universidade de Sao Paulo, Brazil., Viana NI; Department of Urology, Faculdade de Medicina da Universidade de Sao Paulo, Brazil., Reis ST; Department of Urology, Faculdade de Medicina da Universidade de Sao Paulo, Brazil., Mendes KT; Genoa Biotecnologia - Sao Paulo, Brazil., Talib LL; Department of Psychiatry, Faculdade de Medicina da Universidade de Sao Paulo, Brazil., Gattaz WF; Department of Psychiatry, Faculdade de Medicina da Universidade de Sao Paulo, Brazil., Guimarães VR; Department of Urology, Faculdade de Medicina da Universidade de Sao Paulo, Brazil., Silva IA; Department of Urology, Faculdade de Medicina da Universidade de Sao Paulo, Brazil., Pimenta RCP; Department of Urology, Faculdade de Medicina da Universidade de Sao Paulo, Brazil., Camargo JA; Department of Urology, Faculdade de Medicina da Universidade de Sao Paulo, Brazil., Nahas WC; Department of Urology, Faculdade de Medicina da Universidade de Sao Paulo, Brazil., Srougi M; Department of Urology, Faculdade de Medicina da Universidade de Sao Paulo, Brazil., Leite KRM; Department of Urology, Faculdade de Medicina da Universidade de Sao Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	Urologia [Urologia] 2024 Nov; Vol. 91 (4), pp. 720-726. Date of Electronic Publication: 2024 Jul 25.
DOI:	10.1177/03915603241257362
Abstrakt:	Background: Phospholipase A2 (PLA2) is a large family of enzymes involved in the inflammatory process that catalyzes the hydrolysis of membrane phospholipids, leading to the production of free fatty acids and lysophospholipids, starting the arachidonic acid cascade. Their expression has been related to the behavior of several cancers. Our objective is to search for PLA2 expression in prostate cancer (PCa) tissue that correlates with prognosis and survival. Methods: Using qRT-PCR, we analyzed the expression levels of PLA2G1B, PLA2G2A, PLA2G2D, PLA2G4A, PLA2G4B, PLA2G4C, PLA2G4D, PLA2G4E, PLA2G4F, PLA2G6, PLA2G7, PLA2G16, PNPLA1, and PNPLA2 in PCa tissue from 108 patients submitted to radical prostatectomy, followed by a mean time of 163 months. Results: All PLA2 was overexpressed in PCa compared to normal tissue. Interestingly, higher expression of some PLA2 was related to favorable prognostic factors: lower levels of PSA (PLA2G2A, PLA2G4D), lower rates of lymph node metastasis (PLA2G16 and PLA2G1B), and organ-confined disease (PLA2G4A). Most importantly, PLAG4B was independently related to longer disease-free survival. Conclusion: This is the first study exploring comprehensively the expression levels of PLA2 in PCa, showing that the higher expression of some PLA2 should be used as biomarkers of good prognosis and longer disease-free survival. Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu